---
title: "SAB BIOTHERAPEUTICS INC C/WTS 22/10/2026 (TO PUR COM) | 10-Q: FY2025 Q1 EPS: USD -0.56"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/239574053.md"
datetime: "2025-05-09T12:44:20.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/239574053.md)
  - [en](https://longbridge.com/en/news/239574053.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/239574053.md)
generator: "portal-rs"
---

# SAB BIOTHERAPEUTICS INC C/WTS 22/10/2026 (TO PUR COM) | 10-Q: FY2025 Q1 EPS: USD -0.56

EPS: As of FY2025 Q1, the actual value is USD -0.56.

### Segment Revenue

-   **Grant Revenue**: No revenue recognized for the three months ended March 31, 2025, compared to $944,575 for the same period in 2024.

### Operational Metrics

-   **Net Loss**: Net loss of $5,196,773 for the three months ended March 31, 2025, compared to $5,025,745 for the same period in 2024.
-   **Research and Development Expenses**: $7,657,321 for the three months ended March 31, 2025, a decrease from $8,146,070 for the same period in 2024.
-   **General and Administrative Expenses**: $3,114,781 for the three months ended March 31, 2025, a decrease from $4,189,121 for the same period in 2024.

### Cash Flow

-   **Net Cash Used in Operating Activities**: - $7,797,217 for the three months ended March 31, 2025, compared to - $10,750,009 for the same period in 2024.
-   **Net Cash Provided by (Used in) Investing Activities**: $4,671,103 for the three months ended March 31, 2025, compared to - $31,359,207 for the same period in 2024.
-   **Net Cash Used in Financing Activities**: - $173,985 for the three months ended March 31, 2025, compared to - $394,418 for the same period in 2024.

### Unique Metrics

-   **Changes in Fair Value of Warrant Liabilities**: $5,035,769 for the three months ended March 31, 2025, compared to $5,468,219 for the same period in 2024.

### Future Outlook and Strategy

-   **Core Business Focus**: SAB Biotherapeutics plans to advance SAB-142 into a Phase 2b trial in 2025 to evaluate the therapeutic candidate in adult and pediatric patients with new-onset type 1 diabetes.
-   **Non-Core Business**: The company does not expect to generate revenues during the development phase of its primary pipeline development target of Type 1 diabetes, which remains independently financed as it explores potential partnerships, co-development opportunities, and licensing arrangements.

### Related Stocks

- [SABSW.US](https://longbridge.com/en/quote/SABSW.US.md)

## Related News & Research

- [Why Jim Cramer sees CrowdStrike as a buy despite its incredible comeback rally](https://longbridge.com/en/news/297213627.md)
- [How Foot Locker went from a sneakerhead destination to a store struggling to get rid of old shoes](https://longbridge.com/en/news/297208698.md)
- [Nvidia Revenue Set to Increase 18X in 4 Years; Analyst Says 'Never in History' Has a Company Grown This Fast](https://longbridge.com/en/news/297126014.md)
- [Alphabet Is a 'Top 2027 Stock Pick,' Says Wolfe Research Analyst. Here's Why](https://longbridge.com/en/news/297186957.md)
- [Zhongji Innolight Fully Exercises Over-Allotment Option After Hong Kong IPO](https://longbridge.com/en/news/297095479.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**